Pharmaceutical stocks reacted unevenly worldwide after President Trump announced a sweeping new policy targeting foreign-made branded and patented drugs. The 100% tariff, set to take effect on October 1, 2025, will apply to companies not actively building manufacturing facilities in the U.S.<\/p>\n\n\n\n
\u201cStarting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,\u201d Trump announced on his social media site, Truth Social, on Thursday.<\/p>\n\n\n\n
The measure forms part of a broader tariff package, which also includes new duties on large trucks and home goods.<\/p>\n\n\n\n
In Asia, pharma stocks led broader market declines. Japan\u2019s Nikkei Stock Average closed 0.9% lower, dragged down by steep falls in Sumitomo Pharma (-3.45%), Chugai Pharmaceutical (-4.8%), and Daiichi Sankyo (-2.0%). South Korea\u2019s Samsung Biologics dropped 2.15%, while China\u2019s Alibaba Health and JD Health both fell over 4%.<\/p>\n\n\n\n
India also saw losses, with Sun Pharmaceutical Industries sliding 2.9% and Natco Pharma down 3.6%.<\/p>\n\n\n\n
Meanwhile, European markets told a more nuanced story. Large-cap players with significant U.S. investment plans\u2014such as AstraZeneca, GSK, Novartis, Roche, and Sanofi\u2014opened lower but recovered, with some finishing the day in positive territory. Smaller firms, however, fared worse: Genmab and Zealand Pharma slipped nearly 2%, while Novo Nordisk shed 1.5%.<\/p>\n\n\n\n
U.S. big pharma stocks, by contrast, gained slightly in premarket trading, signaling investor confidence that many industry giants will avoid direct impact.<\/p>\n\n\n\n
Economists and analysts noted that the tariff may be less disruptive than headlines suggest. Neil Shearing, group chief economist at Capital Economics, wrote: \u201cThe exemptions for generic drugs and companies constructing U.S. plants will lower the effective tariff rate, as many global firms already have production in the U.S. or plans underway.\u201d<\/p>\n\n\n\n
Analysts at Vontobel echoed this view, highlighting that Novartis and Roche should sidestep the worst of the tariffs thanks to ongoing U.S. facility construction. By contrast, companies like Galderma and other smaller players with limited American operations may face more pronounced pressure.<\/p>\n\n\n\n
Chinese biotechs also face uncertainty. While direct exposure remains low\u2014China represented just 4% of U.S. drug imports in 2024\u2014Jefferies analysts warned that investor sentiment could dampen expansion plans.<\/p>\n\n\n\n
Still, they noted that most Chinese companies partner with U.S. firms, providing a degree of tariff protection.<\/p>\n\n\n\n
While regional stock declines reflect near-term volatility, economists expect the long-term impact on major pharmaceutical groups to remain limited. Barclays pointed out that India\u2019s largely domestic orientation, and the exemption of generics, should help soften potential blows to its sector.<\/p>\n\n\n\n
The new measures, however, add to global uncertainty in both pharmaceuticals and other industries targeted by Trump\u2019s tariff expansion. Heavy trucks, for example, will face a new 25% import duty starting October 1.<\/p>\n\n\n\n
For investors, the initial selloff underscores regional vulnerabilities but also highlights resilience among larger pharmaceutical players with entrenched U.S. operations. The policy may intensify consolidation pressures in the industry, pushing smaller biotechs to seek partnerships or accelerate U.S. investment to remain competitive.<\/p>\n\n\n\n
<\/p>","protected":false},"excerpt":{"rendered":"
Trump\u2019s 100% tariff on foreign-made branded drugs has shaken markets, with analysts warning the impact won\u2019t be evenly felt.<\/p>","protected":false},"author":2,"featured_media":2958,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,55,61,58,57,7],"tags":[64,68,69,72,33,70,31],"class_list":["post-2957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-general","category-pharma-industry","category-latest-global-stock-market-news","category-latest-us-stock-market-news","category-pharma-investments","category-pharmaceutical","tag-biotech","tag-finance","tag-general","tag-industry","tag-investing","tag-north-america","tag-pharmaceutical"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=2957"}],"version-history":[{"count":2,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2957\/revisions"}],"predecessor-version":[{"id":2960,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2957\/revisions\/2960"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/2958"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=2957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=2957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=2957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}